172 related articles for article (PubMed ID: 35705086)
1. [Theranostics for Well and Moderately Differentiated GEP-NEN].
Hartrampf P; Werner R; Buck A
Zentralbl Chir; 2022 Jun; 147(3):249-255. PubMed ID: 35705086
[TBL] [Abstract][Full Text] [Related]
2. Investigation of receptor radionuclide therapy with
Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
[TBL] [Abstract][Full Text] [Related]
3. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging Theranostics of Neuroendocrine Tumors.
Fortunati E; Bonazzi N; Zanoni L; Fanti S; Ambrosini V
Semin Nucl Med; 2023 Jul; 53(4):539-554. PubMed ID: 36623974
[TBL] [Abstract][Full Text] [Related]
7. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with
Alipour R; Jackson P; Bressel M; Hogg A; Callahan J; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2997-3010. PubMed ID: 37184682
[TBL] [Abstract][Full Text] [Related]
8. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
9. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
Alsadik S; Yusuf S; Al-Nahhas A
Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
[TBL] [Abstract][Full Text] [Related]
11. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy.
Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
[TBL] [Abstract][Full Text] [Related]
13. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
15. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
17. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
18. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
[TBL] [Abstract][Full Text] [Related]
19. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.
Di Franco M; Zanoni L; Fortunati E; Fanti S; Ambrosini V
Curr Oncol Rep; 2024 May; 26(5):538-550. PubMed ID: 38581469
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]